These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 13940879)

  • 1. Antigenic characterization of oral poliovaccine progeny by neutralization kinetics.
    OZAKI Y; DIWAN AR; McBRIDE WD; MELNICK JL
    J Immunol; 1963 Feb; 90():288-96. PubMed ID: 13940879
    [No Abstract]   [Full Text] [Related]  

  • 2. Intratypic serodifferentiation of oral poliovaccine progeny.
    Ozaki Y; Takizawa M
    Acta Sch Med Univ Kioto; 1965 Jun; 39(2):81-91. PubMed ID: 4285526
    [No Abstract]   [Full Text] [Related]  

  • 3. ANTIGENIC DIFFERENTIATION OF POLIOVIRUSES BY ABSORBED HYPERIMMUNE SERA. I. ANTIGENIC DIFFERENTIATION OF TYPE I STRAINS OF DIVERSE ORIGIN.
    EYLAN E; FOGEL A; DUKLER R; RANNON L
    J Immunol; 1965 Jul; 95():171-80. PubMed ID: 14328695
    [No Abstract]   [Full Text] [Related]  

  • 4. ANTIGENIC VARIATIONS AMONG TYPE III POLIOMYELITIS VIRUSES.
    DEIBEL R; MACDONALD D
    N Y State J Med; 1964 Aug; 64():2058-65. PubMed ID: 14180893
    [No Abstract]   [Full Text] [Related]  

  • 5. Antigenic characterization of type 3 poliovirus strains isolated (1968-1970) in Italy from vaccinated and unvaccinated patients.
    Marchegiani M; Rocchi G; Santoro R; Puccinelli M
    Ann Inst Pasteur (Paris); 1971 Sep; 121(3):413-8. PubMed ID: 4108589
    [No Abstract]   [Full Text] [Related]  

  • 6. Mapping of type 1 poliovirus neutralization epitopes.
    Blondel B; Crainic R; Dufraisse G; Candréa A; Horaud F
    Dev Biol Stand; 1985; 60():337-42. PubMed ID: 2412917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of antibodies in a population immunized with oral poliovaccine (OPV).
    Srámová H; Teplý V; Svandová E
    J Hyg Epidemiol Microbiol Immunol; 1979; 23(2):212-9. PubMed ID: 231625
    [No Abstract]   [Full Text] [Related]  

  • 8. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.
    Minor PD; Evans DM; Ferguson M; Schild GC; Westrop G; Almond JW
    J Gen Virol; 1985 May; 66 ( Pt 5)():1159-65. PubMed ID: 2582084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Problems with oral poliovaccine in India.
    John TJ
    Indian Pediatr; 1972 May; 9(5):252-6. PubMed ID: 4649422
    [No Abstract]   [Full Text] [Related]  

  • 10. Distribution of poliovirus antibody in serum, nasopharynx and alimentary tract following segmental immunization of lower alimentary tract with poliovaccine.
    Ogra PL; Karzon DT
    J Immunol; 1969 Jun; 102(6):1423-30. PubMed ID: 4977607
    [No Abstract]   [Full Text] [Related]  

  • 11. Antigenic modification of attenuated Sabin type 1 poliovirus by in vitro passages at supraoptimal temperatures.
    Crainic R; Blondel B; Candréa A; Dufraisse G; Horaud F
    Dev Biol Stand; 1985; 60():343-7. PubMed ID: 2995173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [COMPARATIVE ATTEMPTS TO DEMONSTRATE ANTIBODIES AGAINST POLIOMYELITIS VIRUS WITH THE NEUTRALIZATION TEST AND THE IMMUNOFLUORESCENCE METHOD].
    BOSELLA F
    Boll Ist Sieroter Milan; 1964; 43():249-52. PubMed ID: 14199041
    [No Abstract]   [Full Text] [Related]  

  • 13. COMPLEMENT-FIXING ANTIBODY RESPONSE AFTER ADMINISTRATION OF INACTIVATED AND ORAL POLIOVIRUS VACCINES.
    ZAVADOVA H; ZACEK K; VONKA V
    J Hyg Epidemiol Microbiol Immunol; 1963; 7():487-94. PubMed ID: 14114944
    [No Abstract]   [Full Text] [Related]  

  • 14. Differentiation of poliovirus type I isolates in the 1982 epidemic from Sabin-I strain by antigenic and temperature markers.
    Lee CN; Kao CL; Lee CY
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1987 Feb; 20(1):80-8. PubMed ID: 3036431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of monoclonal antibodies prepared with Sabin vaccine viruses for the characterization of poliovirus strains isolated in Canada.
    Wachmann B; Henning D; Armstrong R; Boucher DW; Contreras G; Furesz J
    Dev Biol Stand; 1984; 57():141-9. PubMed ID: 6084605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A survey of antibody level among a population massively administered poliovaccine 25 years ago in Kunming city].
    Hu XM
    Zhonghua Liu Xing Bing Xue Za Zhi; 1987 Oct; 8(5):268-71. PubMed ID: 3449212
    [No Abstract]   [Full Text] [Related]  

  • 17. CYTOLOGY OF THE URINE IN CHILDREN AFTER ORAL POLIOVIRUS VACCINE.
    HART AF; CHERRY JD
    N Engl J Med; 1965 Jan; 272():174-9. PubMed ID: 14222016
    [No Abstract]   [Full Text] [Related]  

  • 18. Monoclonal antibodies to polioviruses. Production of specific monoclonal antibodies to the Sabin vaccine strains.
    Osterhaus AD; van Wezel AL; van Steenis B; Drost GA; Hazendonk TG
    Intervirology; 1981; 16(4):218-24. PubMed ID: 6177658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MARKER TEST OF POLIOVIRUS IN RELATION TO MASS VACCINATION WITH LIVE ORAL VACCINES.
    TOYOSHIMA K; MITSUDA B; TADOKORO J; YAMADA T; KUNITA N
    Biken J; 1963 Jul; 6():57-72. PubMed ID: 14147706
    [No Abstract]   [Full Text] [Related]  

  • 20. [ON THE VIABILITY AND RESISTANCE OF VACCINAL STRAINS OF POLIOVIRUSES IN THE EXTERNAL ENVIRONMENT].
    BYCHKOVSKAIA OV; BABINA NS; IVANOVA OD; KISELEVA LF
    Gig Sanit; 1964 Aug; 29():45-9. PubMed ID: 14249261
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.